Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
BACKGROUND
In the last 10 years several reports have linked oral 5-aminosalicylic acid (5-ASA) therapy to acute and chronic tubulointerstitial nephritis, but to our knowledge only 2 patients have been reported with terminal end-stage renal disease due to mesalazine (5-ASA). After 1 year of treatment with 5-ASA annual monitoring of serum creatinine is recommended.


RESULTS
We report the development of end-stage renal disease in a patient 10 months after the last assessment of serum creatinine, which was normal at 71 micromol/l.


CONCLUSIONS
Because of this dangerous side effect, we would like to recommend 6-monthly assessment of renal function.
Frandsen
Niels Erik
NE
Department of Nephrology, Esbjerg County Hospital, Esbjerg, Denmark. nef@ribeamt.dk
Saugmann
Søren
S
Marcussen
Niels
N
D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects*; D009395:Nephritis, Interstitial / Q000139:chemically induced* / Q000473:pathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine